Chen Chi-Yu, Chiu Hui-Fen, Yeh Ming-Kung, Chang Chih-Ching, Yang Chun-Yuh
Graduate Institute of Pharmaceutical Sciences, Kaohsiung Medical University, 100 Shih-Chuan 1st Road, Kaohsiung 80708, Taiwan.
Pharmacoepidemiol Drug Saf. 2003 Mar;12(2):129-33. doi: 10.1002/pds.810.
To describe the use of anti-asthma drugs in Taiwanese pediatric patients.
Using the data from the database of Bureau of National Health Insurance, we analyze the patterns and extent of medication use among asthma patients less than 18 years old. Drugs were classified according to the Anatomical Therapeutic Chemical (ATC) Classification system.
Data on a total of 2,90,467 children were included in the study. Overall, patients were treated more frequently with oral medications. 69.43 and 40.24% of patients were using oral beta-agonists (OBAs) and methylxanthines respectively. Monotherapy with OBAs was the most popular regimen, accounting for 13.70% of the total prescriptions studied. Only 6.70% of patients were taking inhaled corticosteroids (ICSs). During the studied period, users of ICSs were using an average of 1.65 canisters.
The current practices of asthma management in Taiwan fall short of the goals stated in international guidelines. Anti-inflammatory agents were being underused in Taiwanese pediatric patients.
描述抗哮喘药物在台湾儿科患者中的使用情况。
利用国民健康保险局数据库中的数据，我们分析了18岁以下哮喘患者的用药模式和用药程度。药物根据解剖治疗化学（ATC）分类系统进行分类。
共有290467名儿童的数据纳入研究。总体而言，患者口服药物治疗更为频繁。分别有69.43%和40.24%的患者使用口服β-激动剂（OBA）和甲基黄嘌呤。OBA单一疗法是最常用的治疗方案，占所研究总处方的13.70%。只有6.70%的患者使用吸入性糖皮质激素（ICS）。在研究期间，ICS使用者平均使用1.65罐。
台湾目前的哮喘管理实践未达到国际指南中规定的目标。抗炎药物在台湾儿科患者中使用不足。
